Therapeutic class — broad (HIC1)Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 codeQ3
Therapeutic class — intermediate (HIC2)Anal-Rectal Preparations
HIC3 codeQ3S
Therapeutic class — specific (HIC3)Laxatives, Local/Rectal
AHFS code56:12.00.00
AHFS classCathartics And Laxatives
FDB label nameENEMEEZ PLUS MINI ENEMA
FDB brand nameEnemeez Plus
Legend statusO — Over-the-counter (OTC) drug or device
Why two NDCs?
The FDA registers this code as 17433-9877-3 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 17433-9877-03. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
🏷️RxNorm drug class
This medicine belongs to the Standardized Chemical Allergen class.
Pharmacologic classStandardized Chemical Allergen
Drug family (ATC)Local anesthetics, Anesthetics for topical use, Esters of aminobenzoic acid
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
🩺 Clinical
Label name ENEMEEZ PLUS MINI ENEMAIngredient Docusate Sodium/Benzocaine
🧪 What is this product?
Enemeez Plus is an over-the-counter rectal liquid that contains two active ingredients. Docusate sodium is a stool softener typically used to ease bowel movements and reduce straining. Benzocaine is a local anesthetic commonly used to numb minor pain and discomfort in the rectal area. This product is marketed under FDA's OTC monograph rules for its drug category.
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
💬 Questions about docusate sodium and benzocaine?
Ask a licensed pharmacist directly — free, answered by our team.
Inactive ingredients, also called excipients, are components of the drug product
other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors,
or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
UNII PDC6A3C0OX
Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
UNII 5655G9Y8AQ
A synthetic liquid polymer used as a solvent and humectant in medications. It helps dissolve active ingredients, maintain moisture in the formulation, and improve how the medicine flows and is absorbed.
2 inactive ingredients listed in the exact product block matched to this NDC.
The official label also statesInactive Ingredients Polyethylene Glycol and Glycerin USP
Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.
Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
Price system
Per mL
Per package
Retail pharmacies payNADAC · weekly
$0.368
$55.26 / 150 ml
Medicaid paysCMS SDUD · 12 mo
$0.3847
$57.71 / 150 ml
Medicare drug plans payPart D · quarterly
No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
▲ Up 2% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
⏳ Availability & generic status
🏛️
2012
On the market since
Jun 2012
📍
2026
Currently FDA-listed
14 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
🗺️ Medicaid utilization & spend
📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 17433-9877-03, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
1.6K
Units reimbursed last 4 qtrs
329.1K
Gross reimbursed last 4 qtrs
$126.6K
Avg / prescription
$78.01
Avg / unit
$0.3847
Latest quarter Q1 2026
395Rx
Medicaid pays / mL
$0.3847
gross reimbursed
vs
NADAC / mL
$0.3684
acquisition cost
=
Spread
+$0.0163
+4% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
60% FFS40% MCO
Fee-for-service · 980 Rx Managed care · 643 Rx
State Medicaid map
Units reimbursed · per 100k residents
27.64,329
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
Prescriptions—
Units—
Reimbursed—
🏆 Top states by units · per 100k residents
1Nebraska4,329 /100k
2New York366 /100k
3Ohio305 /100k
4Washington258 /100k
5Texas180 /100k
6California128 /100k
7Massachusetts85.7 /100k
8Michigan40.4 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
💊 Medicaid utilization by pack size
Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
Drug total (last 4 qtrs): 1,623 Rx · 329,070 units · $126,607 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.
🔬 Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for ENEMEEZ Plus (this brand).
Top reported reactions
Constipation2
Drug Withdrawal Syndrome2
Abdominal Pain Upper1
Acute Sinusitis1
Anticoagulation Drug Level Above Therapeutic1
Arthralgia1
Asthenia1
Age at onset
Adult1
Reporter sex
Male · 71%
Female · 29%
Serious outcomes
Hospitalization5
Life-threatening1
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
📦 Packaging — all sizes for this product
Package NDC
Description
Per unit
Per pack
Marketing start
Status
17433-9877-03 You're viewing this
30 TUBE in 1 CONTAINER (17433-9877-3) / 5 mL in 1 TUBE (17433-9877-0)
65 TUBE in 1 CONTAINER (17433-9877-4) / 5 mL in 1 TUBE (17433-9877-0)
—
—
2026-06-30
Active
In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in NDC 17433-9877-03?
NDC 17433-9877-03 is listed by the FDA — 30 tube in 1 container / 5 ml in 1 tube.
What NDC number is used to bill for this package of ENEMEEZ Plus docusate sodium and benzocaine 20 mg/5mL; 283 mg/5mL Liquid?
Bill NDC 17433-9877-03 — the 11-digit billing format is 17433987703. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
📄 FDA label — Drug Facts FDA SPL
The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
Uses For relief of occasional constipation (irregularity). This product generally produces a stimulus and bowel movement in 2 to 15 minutes.
⏱️Dosage and Administration177 words▾
Directions Adults and children 12 years of age and older (with adult supervision) one to three units daily. Children 2 years and over but not more than 12 years should consult a doctor prior to use and not exceed one unit daily (with adult supervision). Twist off and remove tip; Lubricate tip prior to insertion: Place a few drops of water or product on the shaft prior to insertion.
Also apply one of these lubricants to the anus before inserting the enema. With steady pressure, gently insert the tube into the rectum with care to prevent damage to the rectal wall. Squeeze to empty the contents.
Continue squeezing the tube until it is removed from the rectum. Remove the disposable tube and discard. A small amount of liquid may remain in the tube after use.
Positioning: For best results, lay on the left side with knees bent. Alternate Positions: Administer while seated on the toilet. Kneel with the left arm folded comfortably, then lower head and chest forward until side of face is resting on the surface.
⚠️Warnings24 words▾
Warnings For rectal use only. This is not a suppository. Do not take orally. Individuals with sensitivity to Benzocaine should not use this product.
🆘Overdosage17 words▾
In case of accidental ingestion or overdose, get medical help or contact a Poison Control Center immediately.
📦Storage and Handling12 words▾
Other Information Other Information Store at room temperature 15°-30° C (59°-86° F)
🧪Active Ingredient14 words▾
Drug Facts Active ingredient (per mini enema) Docusate Sodium USP 283 mg Benzocaine 20mg
🧪Inactive Ingredients9 words▾
Inactive Ingredients Inactive Ingredients Polyethylene Glycol and Glycerin USP
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.
